Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Stranzl, H; Gabor, S; Mayer, R; Prettenhofer, U; Wurzinger, G; Hackl, A.
Fractionated intraluminal HDR 192Ir brachytherapy as palliative treatment in patients with endobronchial metastases from non-bronchogenic primaries.
Strahlenther Onkol. 2002; 178(8):442-445
Doi: 10.1007/s00066-002-0943-6
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Stranzl-Lawatsch Heidi
- Co-Autor*innen der Med Uni Graz
- Gabor Sabine
- Hackl Arnulf
- Mayer Ramona
- Prettenhofer Ulrike
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Aim: To evaluate the efficacy of iridium-192 high-dose rate (HDR) endobronchial brachytherapy for the palliation of symptoms caused by endobronchial metastases of non-bronchogenic primaries.Patients and Method: Between 1991 and 1998, eleven patients (female n = 3, mate n = 8; age: median 66 years, range 44-81 years) underwent intraluminal HDR brachytherapy for histologically confirmed endobronchial metastases from non-pulmonary primary tumors of various sites like urogenital tract (n = 5), gastrointestinal tract (n = 3), ear/nose/throat (n = 2) and breast (n = 1). The median time between diagnosis of the primary non-bronchogenic tumor and histopathological diagnosis of the endobronchial metastases was 39 months, range 1-99 months. A total dose of 15-20 Gy was delivered in three to four fractions of 5-6 Gy once a week. No palliative chemotherapy was added.Results: Median follow-up after palliative brachytherapy was 15 months (range 1.4-59 months). Objectively, complete endoscopic response was observed in three (27%) patients, and in five (46%) others partial opening of the initially obstructed airway was achieved. Treatment was judged unsuccessful in three (27%) patients. No patient showed up with local progression. At date of analysis five patients were alive with documented residual tumor (80%) or complete response (20%). Relief of symptoms occurred in the vast majority of patients (n = 8, 73%).Conclusion: HDR intraluminal brachytherapy palliates symptoms in patients suffering from endobronchial metastases of nonpulmonary primary tumors. The applied treatment is a safe, effective and well tolerated palliative procedure Leading to an improved patient quality of Life.
- Find related publications in this database (using NLM MeSH Indexing)
- Adenocarcinoma - radiotherapy Adenocarcinoma - secondary
- Adult -
- Aged -
- Aged, 80 and over -
- Brachytherapy - methods
- Breast Neoplasms -
- Bronchial Neoplasms - radiotherapy Bronchial Neoplasms - secondary
- Carcinoma, Renal Cell - radiotherapy Carcinoma, Renal Cell - secondary
- Carcinoma, Squamous Cell - radiotherapy Carcinoma, Squamous Cell - secondary
- Carcinoma, Transitional Cell - radiotherapy Carcinoma, Transitional Cell - secondary
- Dose Fractionation -
- Female -
- Follow-Up Studies -
- Humans -
- Iridium Radioisotopes - administration & dosage
- Kidney Neoplasms -
- Male -
- Middle Aged -
- Palliative Care -
- Prostatic Neoplasms -
- Radiotherapy Dosage -
- Rectal Neoplasms -
- Sigmoid Neoplasms -
- Time Factors -
- Tongue Neoplasms -
- Tonsillar Neoplasms -
- Urinary Bladder Neoplasms -
- Uterine Neoplasms -
- Find related publications in this database (Keywords)
- brachytherapy
- non-bronchogenic primary
- endobronchial metastases